PROTEON Therapeutics

MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE MEDIA RELEASE

**FOR IMMEDIATE RELEASE**

## Proteon Therapeutics Presents New Data on PRT-201 at the Annual Meeting of the American Society of Nephrology in Philadelphia

**Waltham, Mass., Nov. 6, 2008** — Proteon Therapeutics is presenting new data today on a study of PRT-201 in an animal model of vascular access. The abstract, entitled "Local Application of Recombinant Human Type 1 Pancreatic Elastase (PRT-201) to an AVF Increases AVF Blood Flow in a Rabbit Model," is part of a poster session at Renal Week 2008 corresponding to the 41st annual meeting and scientific exposition of the American Society of Nephrology.

Data from the PRT-201 preclinical study demonstrate that AVFs treated with PRT-201 had an increase in AVF blood flow following treatment. Although AVFs are the preferred form of vascular access, it is well documented that 60 percent fail to mature into usable access sites for dialysis. Higher rates of AVF blood flow measured at the time of AVF creation in patients are predictive of successful AVF maturation and usability.

"Vascular access-related complications are a major cause of suffering and hospitalization for dialysis patients," said Timothy P. Noyes, President and CEO of Proteon. "We look forward to pursuing further study of PRT-201 in the human clinical setting as we plan to initiate our AVF Phase 1/2 clinical trial this quarter."

**About PRT-201**
PRT-201 is a recombinant human elastase that is being studied for its ability to improve arteriovenous fistula (AVF) surgery outcomes in patients requiring chronic hemodialysis. PRT-201 has been shown to cause dilation of segments of arteries and veins following topical intraoperative application in animals. Vessel dilation and increased blood flow through the fistula may decrease AVF maturation failure rates. Improved maturation rates may lead to fewer corrective surgical procedures, hospitalizations, lower costs, and less suffering for dialysis patients. PRT-201 also will be studied for its ability to prolong the patency of arteriovenous grafts (AVGs).

**About Proteon Therapeutics**
Proteon Therapeutics, Inc., is a privately held biopharmaceutical company developing novel, first-in-class pharmaceuticals to address the critical medical needs of patients with kidney and vascular diseases. The company is leveraging a unique understanding of tissue remodeling to develop a pipeline of proprietary pharmaceuticals. The company is headquartered in Waltham, Mass., and has research facilities in Kansas City, Mo. For additional information, please visit *www.proteontherapeutics.com*.

**COMPANY CONTACT:**
Timothy Noyes
President and CEO
781-890-0102
*tnoyes@proteontherapeutics.com*

**PRESS CONTACT:**
Steve Walker
Fleishman-Hillard
816-512-2270
*steve.walker@fleishman.com*

###